Milan, Italy - December 19th, 2022 - Tensive is awarded by the European Innovation Council Accelerator for its project REGENERA
Tensive S.r.l., the medical technology company pioneering innovative solutions for reconstructive surgery, announces that it is among the 78 winners of the prestigious EIC Accelerator program (October 2022 cut-off). Tensive was awarded blended finance consisting of a € 2.5 million grant and an additional € 6 million in equity investment.
"This award will be crucial to support Tensive in conducting the upcoming clinical trials towards commercialization to bring our revolutionary technology to patients in need", states Alessandro Tocchio, CSO of Tensive.
Tensive was founded in 2012 with the mission to offer breast cancer survivors the option for natural breast reconstruction after lumpectomy, and breast augmentation patients a superior aesthetic outcome through an innovative bio-absorbable implant supporting tissue self-regeneration.
"Our vision is to improve lumpectomy patients' quality of life and restore their femininity, avoiding recurrent, painful and expensive surgical operations", states Valentina Morigi, CFO of Tensive.
The loss of a breast can cause a negative psychological impact on breast cancer patients beyond the frightening tumor diagnosis. Among other traumatizing consequences, they experience the loss of femininity and breast sensation. "By using a device designed to be gradually degraded in the body over time and safely replaced by the patient's soft tissue, breast cancer survivors will preserve a natural breast aspect", states Margherita Tamplenizza, CQA&RAO of Tensive.
"Unlike silicone implants and fat grafting, our solution aims to offer a safe, single-surgery option for breast reconstruction with the goal to drastically reduce pain, costs and stress for patients and the healthcare system", states Irini Gerges, CTO of Tensive
"We'd like to thank our team, partners, and quota holders who supported us and worked relentlessly throughout the years towards our ambitious mission," states Alberto Cantaluppi, President of Tensive.
"The award of the EIC Accelerator program represents a further validation of Tensive's vision. We expect that this acknowledgment will enable us to attract additional private investors and venture capitalists to join our company, accelerate market entry, and commercialization", states Federico Martello, CEO of Tensive.
The EIC Accelerator offers start-ups and SMEs grants of up to €2.5 million combined with equity investments through the EIC Fund ranging from €0.5 to €15 million. In addition to financial support, all projects benefit from a range of Business Acceleration Services that provide access to leading expertise, corporates, investors, and ecosystem actors.
EIC announcement: https://eic.ec.europa.eu/news/european-innovation-council-welcomes-78-high-potential-start-ups-and-smes-highly-competitive-2022-12-19_en
For more information about Tensive: https://www.tensivemed.com
Media Relations: email@example.com